Skip to main content

FSNUF · Fresenius SE & Co. KGaA

Track FSNUF — free
$56.50 At close · Nov 20
Market Cap
$31.59B
Shares
2.25B
Volume · Nov 20 201 Avg daily vol (2 sessions) 62.65K

Price & Indicators

 

Key stats

Close
$56.50
Fri 20 Nov
Open
$56.50
Fri 20 Nov
Average volume, 30 days
6K
shares a session
Short interest
592K
0.0% of shares · 999+ days to cover
Day range
$56.50$56.50
Open $56.50 Close $56.50
52-week closing range
$46.86$57.00
Close $56.50 0.9% under the high
Short volume, last session
100%
Last earnings
Nov 4, 2026
Price history
Jan 2020 to Nov 2026

Up next

Feb 24, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 4
Earnings call
Raises guidance after 14% core EPS growth

Fresenius reported Q3 organic revenue growth of 5% and core EPS growth of 14% at constant currency. It raised full-year core EPS guidance to the upper half of 10% to 15% and group EBIT margin guidance to above 11.5%.

4 source passages
Fresenius has delivered another excellent quarter. In summary, Q3 results demonstrate continued execution across the group. We delivered 5% organic revenue growth, expanded margins, and increased core EPS by 14% while investing in our growth vectors and maintaining leverage at 2.5 times. we now expect 4 EPS growth in the upper half of our 10 to 15% guidance range. We are also increasing our group EBIT margin indication to above 11.5%. Organic revenue grew 5%, translating into double-digit EBIT growth at constant currency. Open the document at this passage
All documents

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 4, 2026
full-year indication
Tax rate 24% – 25%
EBIT margin 16.5% – 17%
full-year
Group EBIT margin at least 11.5%
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Kabi EBIT margin · full-year 17%
CapEx as percent of revenue · full-year 5.5%
Kabi organic revenue growth · second half 7%
Kabi pharma EBIT margin · second half 20%
Core EPS growth at constant currency · full year 10% – 15%
Kabi EBIT margin · full year 16.5% – 17%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $43 › 200d $32 — 50d above 200d
Institutional flow Accumulating
+60% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.03% of shares out · ▼ -16.2% MoM · 1000.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
8 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $47 Now $57 · 95% Range high $57
vs 200-day avg +75% vs 50-day avg +33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FSNUF
Fresenius SE & Co. KGaA
this stock
$31.59B — — — —
HCA
HCA Healthcare, Inc.
$99.34B +1.9% +7.1% 15.8 2.3%
THC
Tenet Healthcare Corp
$20.95B +32.4% +0.9% 7.6 2.2%
EHC
Encompass Health Corp
$13.11B +25.9% +10.5% 20.9 3.7%
FMS
Fresenius Medical Care AG
$10.61B -14.2% +5.9% — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
8
% held
0.0%
Net QoQ
+21.6K sh
Top holder
Sterling Capital Manageme…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
592.0K
Days to cover
1000.0d
Change
-114.7K sh
View
Short Volume
Short vol %
100%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
258.7K
Value
$3.3M
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Fresenius receives Building Publi…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
FSNUF +8.9% +49.8% +103.8% +20.6% +1.1%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +17.4% +59.0% +113.0% +29.3% -0.1%
Key facts CIK 904868 CUSIP 35804M105 Visit website Investor relations